[ad_1]
A woman prepares for a swab examination at her home.
d3sign | moment | Getty Images
Goldman Sachs is starting to cover the fast-growing, high-margin health technology sector that it says is poised for a post-pandemic boost.
Wall Street analysts have released stock valuations in the diagnostics sector for the first time, selecting four companies they say are innovative and can diversify revenue across multiple products, according to a research note published Wednesday.
Coronavirus testing has become a part of everyday life for many people – and that means speeding up the licensing process for such kits.
As a result, Goldman says, companies in the diagnostics sector are likely to emerge from the pandemic “stronger and faster growth,” buoyed by a faster approval process for health tests as well as cheaper technology and increased demand from an aging population.
The buying-rated bank’s choices are:
.
[ad_2]
Picture Credit!